Testing Promising Drug-like Compounds Against Rare but Fatal Parasitic Amoeba, Naegleria

Presenter Type

UNO Undergraduate Student

Major/Field of Study

Biology

Other

Molecular & Biomedical Biology

Advisor Information

Dr.

Location

CEC RM #116

Presentation Type

Oral Presentation

Start Date

22-3-2024 9:00 AM

End Date

22-3-2024 10:15 AM

Abstract

Naegleria fowleri is a parasitic amoeba that resides in warm freshwater and causes meningoencephalitis in humans. While infection is rare, the mortality rate is 97% as the current recommended treatment regimens are unreliable and have proven ineffective. There have even been fatalities in Nebraska and Iowa in recent years. Our aim is to find novel compounds or repurposed drugs with promise to be effective in treating the amoeba. While in vitro studies can help to identify potential lead compounds, little work has been done further – such as in animal models - thus impeding the progress of promising compounds. Here we will present several promising compounds with potency in vitro and discuss the path towards clinical development and approval.

This document is currently not available here.

COinS
 
Mar 22nd, 9:00 AM Mar 22nd, 10:15 AM

Testing Promising Drug-like Compounds Against Rare but Fatal Parasitic Amoeba, Naegleria

CEC RM #116

Naegleria fowleri is a parasitic amoeba that resides in warm freshwater and causes meningoencephalitis in humans. While infection is rare, the mortality rate is 97% as the current recommended treatment regimens are unreliable and have proven ineffective. There have even been fatalities in Nebraska and Iowa in recent years. Our aim is to find novel compounds or repurposed drugs with promise to be effective in treating the amoeba. While in vitro studies can help to identify potential lead compounds, little work has been done further – such as in animal models - thus impeding the progress of promising compounds. Here we will present several promising compounds with potency in vitro and discuss the path towards clinical development and approval.